Global market for cloud computing in healthcare is expected to reach $5.4 bln by 2017
The cloud computing market is expected to expand by an estimated 20.5% over the next five years to become a $5.4 billion market by 2017, according to Healthcare Cloud Computing Market- Global Trends, Challenges, Opportunities and Forecasts.
The healthcare spending on the cloud hovers around $1.8 billion as of 2011 despite market penetration of about 4%.
Markets and Markets said in the report, “The market is witnessing a surge in the adoption of technology, and cloud computing is expected to bring about a revolution in the healthcare IT market.”
It also noted that healthcare companies are expected to deliver more with fewer resources, which is helping to fuel the growth in the usage of cloud.
The study states, the healthcare data has very specific needs when it comes to security, confidentiality, availability to authorized users, traceability of access, reversibility of data and long-term preservation.
The study also noted that North America is the largest market for healthcare cloud solutions. The largest players are CareCloud, GE Healthcare, Carestream Health and Merge Healthcare.
The report also said, “Doctor’s clinics, hospitals, and health clinics require quick access to computing and large storage facilities which are not provided in traditional settings.”
The report also said, “Moreover, healthcare data needs to be shared across various settings and geographies which further burdens the healthcare provider and the patient causing significant delay in loss of time. Cloud caters to all these requirements thus providing the healthcare organizations an incredible opportunity to improve services.”
Cloud computing is the use of computing resources that are delivered as a service over a network. The name comes from the use of a cloud-shaped symbol as an abstraction for complex infrastructure it contains in system diagrams.
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.